Abstract
The development of resistance toward current cancer therapy modalities is an ongoing challenge in gynecological cancers, especially ovarian and cervical malignancies that require further investigations in the context of drug- and irradiation-induced resistance. In this regard, curcumin has demonstrated beneficial and highly pleiotropic actions and increased the therapeutic efficiency of radiochemotherapy. The antiproliferative, anti-metastatic, anti-angiogenic, and anti-inflammatory effects of curcumin have been extensively reported in the literature, and it could also act as a chemopreventive agent which mitigates the out-of-target harmful impact of chemotherapeutics on surrounding normal tissues. The current review discussed the modulating influences of curcumin on some cell and molecular features, including the cell signaling and molecular pathways altered upon curcumin treatment, the expression of target genes involved in the progression of gynecological cancers, as well as the expression of genes accountable for the development of resistance toward common chemotherapeutics and radiotherapy. The cell molecular targets implicated in curcumin’s resensitizing effect, when used together with cisplatin, paclitaxel, and irradiation in gynecological cancers, are also addressed. Finally, rational approaches for improving the therapeutic benefits of curcumin, including curcumin derivatives with enhanced therapeutic efficacy, using nanoformulations to advance curcumin stability in physiological media and improve bioavailability have been elucidated.
The original version of this chapter was revised. A correction to this chapter is available at DOI: 10.1007/112_2018_14.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsChange history
08 December 2018
The affiliation of the 6th author Dr. Abolfazl Mehdizadehkashi was incorrect. It has been corrected to Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran.
Abbreviations
- CDK:
-
Cyclin-dependent kinase
- COX-2:
-
Cyclooxygenase-2
- Cur:
-
Curcumin
- DNMTs:
-
DNA methyltransferases
- GSTs:
-
Glutathione S-transferases
- HDAC:
-
Histone deacetylases
- IAPs:
-
Inhibitor of apoptosis family of proteins
- ICAM-1:
-
Intercellular adhesion molecule 1
- IKK:
-
IκB kinase
- iNOS:
-
Inducible nitric oxide synthase
- MT:
-
Metallothionein
- P-gp:
-
P-glycoprotein
- PI3K:
-
Phosphatidylinositide 3-kinase
- VEGF:
-
Vascular endothelial growth factor
References
Abdollahi E, Momtazi AA, Johnston TP, Sahebkar A (2018) Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: a nature-made jack-of-all-trades? J Cell Physiol 233:830–848
Abouzeid AH, Patel NR, Sarisozen C, Torchilin VP (2014) Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells. Pharm Res 31:1938–1945
Aggarwal BB, Harikumar KB (2009) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41:40–59
Ak T, Gülçin İ (2008) Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact 174:27–37
Aqil F, Munagala R, Jeyabalan J, Agrawal AK, Gupta R (2017) Exosomes for the enhanced tissue bioavailability and efficacy of curcumin. AAPS J 19:1691–1702
Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ (2005) Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280:6301–6308
Chan MM, Fong D, Soprano KJ, Holmes WF, Heverling H (2003) Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol 194:63–70
Chen P, Li J, Jiang H-G, Lan T, Chen Y-C (2015a) Curcumin reverses cisplatin resistance in cisplatin-resistant lung cancer cells by inhibiting FA/BRCA pathway. Tumor Biol 36:3591–3599
Chen Q, Gao Q, Chen K, Wang Y, Chen L, Li X (2015b) Curcumin suppresses migration and invasion of human endometrial carcinoma cells. Oncol Lett 10:1297–1302
Cheng SCS, Luo D, Xie Y (2001) Taxol induced BCL-2 protein phosphorylation in human hepatocellular carcinoma QGY-7703 cell line. Cell Biol Int 25:261–265
Debata PR, Castellanos MR, Fata JE, Baggett S, Rajupet S, Szerszen A, Begum S, Mata A, Murty VV, Opitz LM (2013) A novel curcumin-based vaginal cream Vacurin selectively eliminates apposed human cervical cancer cells. Gynecol Oncol 129:145–153
Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, Dicato M, Diederich M (2005) Chemopreventive and therapeutic effects of curcumin. Cancer Lett 223:181–190
Ganta S, Amiji M (2009) Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 6:928–939
Garcea G, Jones D, Singh R, Dennison A, Farmer P, Sharma R, Steward W, Gescher A, Berry D (2004) Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90:1011–1015
Giannakakou P, Sackett DL, Kang Y-K, Zhan Z, Buters JT, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118–17125
Hajavi J, Abbas Momtazi A, Johnston TP, Banach M, Majeed M, Sahebkar A (2017) Curcumin: a naturally occurring modulator of adipokines in diabetes. J Cell Biochem 118:4170–4182
Huq F, Yu JQ, Beale P, Chan C, Arzuman L, Nessa MU, Mazumder ME (2014) Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer. Anticancer Res 34:541–545
Javvadi P, Segan AT, Tuttle SW, Koumenis C (2008) The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol Pharmacol 73:1491–1501
Javvadi P, Hertan L, Kosoff R, Datta T, Kolev J, Mick R, Tuttle SW, Koumenis C (2010) Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Cancer Res 70:1941–1950
Kasinski AL, Du Y, Thomas SL, Zhao J, Sun S-Y, Khuri FR, Wang C-Y, Shoji M, Sun A, Snyder JP (2008) Inhibition of IκB kinase-nuclear factor-κB signaling pathway by 3, 5-bis (2-flurobenzylidene) piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol 74:654–661
Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB, Rao CV, Reddy BS (1999) Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 59:597–601
Kumar SSD, Surianarayanan M, Vijayaraghavan R, Mandal AB, Macfarlane D (2014) Curcumin loaded poly (2-hydroxyethyl methacrylate) nanoparticles from gelled ionic liquid–In vitro cytotoxicity and anti-cancer activity in SKOV-3 cells. Eur J Pharm Sci 51:34–44
Kuttan G, Kumar KBH, Guruvayoorappan C, Kuttan R (2007) Antitumor, anti-invasion, and antimetastatic effects of curcumin. In: The molecular targets and therapeutic uses of curcumin in health and disease. Springer, Boston
Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6:10
Li C, Ge X, Wang L (2017) Construction and comparison of different nanocarriers for co-delivery of cisplatin and curcumin: a synergistic combination nanotherapy for cervical cancer. Biomed Pharmacother 86:628–636
Liu Z, Zhu Y-Y, Li Z-Y, Ning S-Q (2016) Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells. Oncol Lett 12:3944–3948
Mancarella S, Greco V, Baldassarre F, Vergara D, Maffia M, Leporatti S (2015) Polymer-coated magnetic nanoparticles for curcumin delivery to cancer cells. Macromol Biosci 15:1365–1374
Maruthur NM, Bolen SD, Brancati FL, Clark JM (2009) The association of obesity and cervical cancer screening: a systematic review and meta-analysis. Obesity 17:375–381
Mishra S, Kapoor N, Ali AM, Pardhasaradhi B, Kumari AL, Khar A, Misra K (2005a) Differential apoptotic and redox regulatory activities of curcumin and its derivatives. Free Radic Biol Med 38:1353–1360
Mishra S, Narain U, Mishra R, Misra K (2005b) Design, development and synthesis of mixed bioconjugates of piperic acid–glycine, curcumin–glycine/alanine and curcumin–glycine–piperic acid and their antibacterial and antifungal properties. Bioorg Med Chem 13:1477–1486
Momtazi AA, Shahabipour F, Khatibi S, Johnston TP, Pirro M, Sahebkar A (2016) Curcumin as a MicroRNA regulator in cancer: a review. Rev Physiol Biochem Pharmacol 171:1–38
Momtazi-Borojeni AA, Haftcheshmeh SM, Esmaeili S-A, Johnston TP, Abdollahi E, Sahebkar A (2017) Curcumin: a natural modulator of immune cells in systemic lupus erythematosus. Autoimmun Rev 17:125–135
Montopoli M, Ragazzi E, Froldi G, Caparrotta L (2009) Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells. Cell Prolif 42:195–206
Nessa MU, Beale P, Chan C, Yu JQ, Huq F (2012) Studies on combination of platinum drugs cisplatin and oxaliplatin with phytochemicals anethole and curcumin in ovarian tumour models. Anticancer Res 32:4843–4850
Pan W, Yang H, Cao C, Song X, Wallin B, Kivlin R, Lu S, Hu G, Di W, Wan Y (2008) AMPK mediates curcumin-induced cell death in CaOV3 ovarian cancer cells. Oncol Rep 20:1553–1559
Panahi Y, Ahmadi Y, Teymouri M, Johnston TP, Sahebkar A (2018) Curcumin as a potential candidate for treating hyperlipidemia: a review of cellular and metabolic mechanisms. J Cell Physiol 233:141–152
Paulraj F, Abas F, Lajis NH, Othman I, Hassan SS, Naidu R (2015) The curcumin analogue 1, 5-bis (2-hydroxyphenyl)-1, 4-pentadiene-3-one induces apoptosis and downregulates E6 and E7 oncogene expression in HPV16 and HPV18-infected cervical cancer cells. Molecules 20:11830–11860
Peng S, Xu Q, Ling XB, Peng X, Du W, Chen L (2003) Molecular classification of cancer types from microarray data using the combination of genetic algorithms and support vector machines. FEBS Lett 555:358–362
Punfa W, Yodkeeree S, Pitchakarn P, Ampasavate C, Limtrakul P (2012) Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. Acta Pharmacol Sin 33:823–831
Rezaee R, Momtazi AA, Monemi A, Sahebkar A (2016) Curcumin: a potentially powerful tool to reverse cisplatin-induced toxicity. Pharmacol Res 117:218–227
Roy M, Mukherjee S (2014) Reversal of resistance towards cisplatin by curcumin in cervical cancer cells. Asian Pac J Cancer Prev 15:1403–1410
Saengkrit N, Saesoo S, Srinuanchai W, Phunpee S, Ruktanonchai UR (2014) Influence of curcumin-loaded cationic liposome on anticancer activity for cervical cancer therapy. Colloids Surf B Biointerfaces 114:349–356
Sarisozen C, Abouzeid AH, Torchilin VP (2014) The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors. Eur J Pharm Biopharm 88:539–550
Sharma R, Jadav SS, Yasmin S, Bhatia S, Khalilullah H, Ahsan MJ (2015) Simple, efficient, and improved synthesis of Biginelli-type compounds of curcumin as anticancer agents. Med Chem Res 24:636–644
Singh AK, Misra K (2013) Human papilloma virus 16 E6 protein as a target for curcuminoids, curcumin conjugates and congeners for chemoprevention of oral and cervical cancers. Interdiscip Sci Comput Life Sci 5:112
Soflaei S, Momtazi A, Majeed M, Derosa G, Maffioli P, Sahebkar A (2017) Curcumin: a natural pan-HDAC inhibitor in cancer. Curr Pharm Des 24:123–129
Song Y-K, Kim C-K (2006) Topical delivery of low-molecular-weight heparin with surface-charged flexible liposomes. Biomaterials 27:271–280
Sreekanth C, Bava S, Sreekumar E, Anto R (2011) Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene 30:3139–3152
Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Terao T (2004) Transforming growth factor-β1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. J Biol Chem 279:8567–8576
Teymouri M, Farzaneh H, Badiee A, Golmohammadzadeh S, Sadri K, Jaafari MR (2015) Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: in vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma. Eur J Pharm Sci 80:66–73
Teymouri M, Badiee A, Golmohammadzadeh S, Sadri K, Akhtari J, Mellat M, Nikpoor AR, Jaafari MR (2016) Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: an in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity. Int J Pharm 511:236–244
Teymouri M, Pirro M, Johnston TP, Sahebkar A (2017) Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: a review of chemistry, cellular, molecular, and preclinical features. Biofactors 43:331–346
Teymouri M, Barati N, Pirro M, Sahebkar A (2018) Biological and pharmacological evaluation of dimethoxycurcumin: a metabolically stable curcumin analogue with a promising therapeutic potential. J Cell Physiol 233:124–140
Wang W-M, Cheng H-C, Liu Y-C, Chang Y-L, Liu S-T (2011) Effect of dimethoxycurcumin beyond degradation of androgen receptor. Dermatol Sin 29:115–120
Watson JL, Greenshields A, Hill R, Hilchie A, Lee PW, Giacomantonio CA, Hoskin DW (2010) Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol Carcinog 49:13–24
Xu Y-Q, Chen W-R, Tsosie JK, Xie X, Li P, Wan J-B, He C-W, Chen M-W (2016) Niosome encapsulation of curcumin. J Nanomater 2016:15
Yang YL, Ji C, Cheng L, He L, Lu CC, Wang R, Bi ZG (2012) Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells. Cancer Sci 103:1538–1545
Yunos NM, Beale P, Yu JQ, Huq F (2011) Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells. Anticancer Res 31:1131–1140
Yusuf R, Duan Z, Lamendola D, Penson R, Seiden M (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3:1–19
Zaman MS, Chauhan N, Yallapu MM, Gara RK, Maher DM, Kumari S, Sikander M, Khan S, Zafar N, Jaggi M (2016) Curcumin nanoformulation for cervical cancer treatment. Sci Rep 6:20051
Zhang J, Liu J, Xu X, Li L (2017) Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer. Cancer Chemother Pharmacol 79:479–487
Acknowledgment
The authors would like to say special thanks to Dr. Amir Saberi-Demneh and Dr. Leila Ghalichi for their guidance and kindness.
Conflict of Interest
The authors declare that they have no conflicts of interest about this report.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Momtazi-Borojeni, A.A. et al. (2018). Curcumin in Advancing Treatment for Gynecological Cancers with Developed Drug- and Radiotherapy-Associated Resistance. In: de Tombe, P., Gudermann, T., Jahn, R., Lill, R. (eds) Reviews of Physiology, Biochemistry and Pharmacology 176. Reviews of Physiology, Biochemistry and Pharmacology, vol 176. Springer, Cham. https://doi.org/10.1007/112_2018_11
Download citation
DOI: https://doi.org/10.1007/112_2018_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-14026-7
Online ISBN: 978-3-030-14027-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)